Skip to main content
Gain Therapeutics, Inc. logo

Gain Therapeutics, Inc. — Investor Relations & Filings

Ticker · GANX ISIN · US36269B1052 US Manufacturing
Open in API
Filings indexed 217 across all filing types
Latest filing 2023-04-28 Proxy Solicitation & In…
Country US United States of America
Listing US GANX

About Gain Therapeutics, Inc.

https://www.gaintherapeutics.com/

Gain Therapeutics, Inc. is a clinical-stage biotechnology company that discovers and develops next-generation allosteric small molecule therapies. The company utilizes its proprietary Magellan™ drug discovery platform, which combines artificial intelligence with physics-based computational models to identify novel allosteric binding sites on disease-implicated proteins. This approach aims to modulate protein function to treat diseases that are currently undruggable. The company's lead candidate, GT-02287, is in Phase I clinical trials for the treatment of GBA-Parkinson’s disease. Gain's therapeutic pipeline targets neurodegenerative diseases, lysosomal storage disorders, and other conditions with high unmet medical needs.

Recent filings

Filing Released Lang Actions
DEFA14A
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Schedule 14A proxy statement filed with the SEC, specifically labeled as "Definitive Additional Materials" related to the Annual Meeting of Stockholders for Gain Therapeutics, Inc. It includes information about the availability of proxy materials, voting instructions, meeting date, and agenda items such as election of directors and ratification of auditors. The text explicitly states it is a proxy statement and provides instructions for accessing the full proxy materials and annual report. The document is not the full proxy statement itself but an additional notice regarding the proxy materials and meeting. Given the content and nature, this fits the category of Proxy Solicitation & Information Statement (PSI). The document length (6047 characters) supports it being a substantive notice rather than a brief announcement. Therefore, the classification is PSI with high confidence.
2023-04-28 English
DEF 14A
Proxy Solicitation & Information Statement
2023-04-28 English
FORM 8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report pursuant to the Securities Exchange Act of 1934. The content focuses on the departure of a director/officer, specifically the separation agreement and related compensatory arrangements for the former CFO. There are no financial statements or earnings data presented, nor is this an announcement of a report publication. The key item is Item 5.02, which relates to departure and appointment of directors or officers. Therefore, this document fits the category of Board/Management Information (MANG). The document length is 6450 characters, which is sufficient to contain substantive details about the management change rather than a brief announcement. Hence, the classification is MANG with high confidence.
2023-04-28 English
FORM 4 SUBMISSION
Director's Dealing
2023-04-12 English
FORM 3 SUBMISSION
Director's Dealing
2023-04-12 English
FORM 8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is used for current reports about significant events. The content specifically details the appointment of a new Chief Financial Officer, including employment terms and severance arrangements. This corresponds to announcements about changes in senior management. There is no financial data or report analysis, so it is not an Annual Report, Interim Report, or Earnings Release. The document is not a proxy statement, voting results, or a regulatory filing of another type. Therefore, the classification best fitting this document is Board/Management Information (MANG). The document length and detail support a high confidence in this classification.
2023-04-12 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.